Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

398
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

440
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
440
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

839
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
839
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

578
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
578
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

511
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NHANES and the rise of environmental cardiology: Metals, mortality, and the maturation of preventive evidence.

American journal of preventive cardiology·2026
Same author

Incidence and prognostic value of electrocardiographic changes in patients with myocardial injury after elective PCI.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Association of the C-reactive protein-triglyceride-glucose index (CTI) with lower-extremity peripheral artery disease among U.S. adults.

Atherosclerosis plus·2026
Same author

Design and rationale of the Radial Access Insertion Sheath Evaluation via the electronic medical record (RAISE-EMR) study.

American heart journal·2026
Same author

Racial and ethnic differences and temporal changes in outcomes following transcatheter aortic valve replacement in urban hospitals.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Living After Pulmonary Embolism: Emotional Recovery, Social Impact, and Guideline Reflections.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Mar 26, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Glycemic Control in Coronary Revascularization.

Francisco Ujueta1,2, Ephraim N Weiss1,2, Steven P Sedlis1,2

  • 1VA New York Harbor Healthcare System, Manhattan Campus, New York, NY, USA.

Current Treatment Options in Cardiovascular Medicine
|January 29, 2016
PubMed
Summary
This summary is machine-generated.

Peri-procedural hyperglycemia increases cardiovascular risks during coronary revascularization. Continuing existing diabetes medications may be the simplest way to manage blood glucose and reduce adverse events.

Keywords:
Coronary artery bypass graft surgeryCoronary revascularizationHyperglycemiaPercutaneous coronary intervention

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K

Related Experiment Videos

Last Updated: Mar 26, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Hyperglycemia during coronary revascularization is linked to adverse cardiovascular outcomes in diabetic and non-diabetic patients.
  • Acute peri-procedural hyperglycemia exacerbates inflammation, platelet activity, endothelial dysfunction, plaque instability, and infarct size.

Purpose of the Study:

  • To review the impact of peri-procedural hyperglycemia on cardiovascular events.
  • To evaluate current treatment strategies for managing hyperglycemia in this context.
  • To explore potential alternative therapeutic approaches.

Main Methods:

  • Review of randomized clinical trials on glucose-insulin-potassium infusions and insulin therapy.
  • Analysis of data linking peri-procedural blood glucose levels to adverse outcomes.
  • Discussion of the efficacy of continuing long-acting glucose-lowering medications.

Main Results:

  • Glucose-insulin-potassium infusions have shown no benefit in improving outcomes.
  • Insulin therapy versus standard care yielded mixed results, often failing to achieve euglycemia.
  • No specific glucose-lowering agent has proven superior for peri-procedural glycemic control.

Conclusions:

  • Continuing pre-existing long-acting glucose-lowering medications may be the most effective strategy for maintaining euglycemia and mitigating harm.
  • Targeting underlying mechanisms, such as potent anti-platelet or anti-inflammatory therapies, warrants further investigation.